THE objective of this study was to determine whether arachidonate metabolites are involved in the vasoconstrictive effects of angiotensin H in rats. In the isolated perfused heart, dexamethasone (4 mg/kg) significantly suppressed the maximal decreases in coronary flow induced by angiotensin H and vasopressin (reference drug). In the heart, the nonselective lipoxygenase inhibitor nordihydroguaiaretic acid (NDGA, IM) markedly suppressed the angiotensin H-induced decreases in coronary flow. NDGA (10 M) inhibited both angiotensin H-and methoxamine-(reference drug) induced contractions in aortic rings with (in the presence of L-NAME) and without endotheHum. In the heart, the leukotriene synthesis inhibitor MK-886 (0.3M) significantly reduced the maximal effects to angiotensin H, but the leukotriene antagonist FPL 55712 (0.1 and 0.3 M) had no effect. We conclude that in the isolated perfused rat heart angiotensin H-induced decreases in coronary flow are in part mediated by Hpoxygenase products, which might be derived from the 5-Hpoxygenase pathway, but are probably not leukotrienes. Furthermore, endotheHum independent Hpoxygenase products mediate part of the contractile responses to angiotensin H in the isolated rat aorta.
Introduction
Vascular angiotensin II is involved in the longterm regulation of blood vessel function and structure and is a major pathophysiological factor in hypertension, atherosclerosis and restenosis. There is accumulating evidence for the presence of a complete renin-angiotensin system in the heart, and a functional role has been suggested. [2] [3] [4] [5] Locally generated angiotensin II could be of importance in the regulation of coronary flow, as has for instance been demonstrated in patients with microvascular angina (Syndrome X). 6 Furthermore, angiotensin II has a direct effect on protein synthesis, which contributes to cardiac hypertrophy. 7 It is well known that angiotensin II exerts its effects through stimulation of inositol phospholipid metabolism. Angiotensin II activates phospholipase C, which hydrolyses phosphatidylinositol biphosphate into inositol triphosphate and 1,2-diacylglycerol. 8 In addition, it has been demonstrated recently that 12-1ipoxygenase activation plays a key role in, e.g. angiotensin IIinduced vascular smooth muscle cell hypertrophy. 9 Other studies have shown that arachidonate metabolites contribute to were selective for angiotensin II we also tested methoxamine and vasopressin as agonists, which like angiotensin II exert their effects through stimulation of inositol phospholipid metabolism. We examined the cyclo-oxygenase pathway in the effects of angiotensin II by using the cyclooxygenase inhibitor indomethacin, the lipoxygenase pathway was studied by using the nonselective lipoxygenase (and cyclo-oxygenase) inhibitor nordihydroguaiaretic acid (NDGA), the (C) there was no change in maximal effect (Fig. 7c ).
The lipoxygenase inhibitor had no effect on the baseline tension of these rings (data not shown).
Effects of indomethacin and AA 86I on angiotensin II-, and methoxamine-induced contractions in aortic rings without endothelium. AA 861 (10 btM) and indomethacin (10 l.tM) had no effect on the contractile responses to both angiotensin II and methoxamine ( (Fig. 8, left" panels) .
t-NAME 100 l.tM significantly increased the con- (Fig. 8, left panels) .
In the presence of -NAME a second concentration-response curve was constructed for angiotensin II and methoxamine after incubation with either 0.1% ethanol (control) or 10M
NDGA. In contrast to methoxamine, the maximal effect to angiotensin II of the second concentration-response curve was significantly lower compared to the first concentration-response curve. The lipoxygenase inhibitor significantly attenuated the maximal contraction to angiotensin II and shifted the concentration-response curve of methoxamine to the right (Fig. 8, right panels) (minimal) contribution of the AT2-receptor to the effects of angiotensin II. The pA2 value of losartan in the heart and aorta was 8. angiotensin II-induced decreases in coronary flow and inhibited the angiotensin II-induced
From our results we can conclude that: (1) in contractions in the aorta in a concentration the coronary system of the rat, part of the anglodependent manner, while the cyclo-oxygenase tensin II-induced decreases in coronary flow are inhibitor indomethacin had no effect in both mediated by lipoxygenase products and not by tissues. NDGA, which is known to be a dual cyclo-oxygenase products; (2) 5-1ipoxygenase. 228 MK-886 is selective for the the concentration-response curve was observed 5-1ipoxygenase pathway of arachidonate acid and no effect or a minor effect on the maximal metabolism since it has no effect on 12-1ipoxy-contractions was seen. In accordance with our genase or cyclo-oxygenase, 26 Indomethacin alone had no effect on angioteninduced a significant increase in baseline corosin II-induced constrictions in both aorta and nary flow suggesting that rat coronary flow is heart. The lack of effect for indomethacin on controlled in part by endogenously produced angiotensin II-induced contractions in rat aorta leukotrienes and perhaps other lipoxygenase was also shown in other studies. 3 However, in products. In accordance, several investigators the presence of AA 861 we observed a marked have found that AA 861, FPL 55712 and NDGA inhibitory effect of indomethacin on angiotensin increased baseline coronary flow in perfused rat II-induced effects in the isolated perfused heart, and guinea pig hearts. 33'34 A role for cyclo-oxygeIn guinea-pig hearts indomethacin induced shuntnase products in the regulation of rat coronary ing of the arachidonate metabolism through the flow is not likely, since indomethacin did not lipoxygenase pathway. 32 Such a mechanism affect baseline coronary flow in rats. We used might enhance the synthesis of lipoxygenase procontrol groups with SNP in sufficient concentraducts leading to e.g. Experiments with 5-HPETE and/or 5-HETE to study whether the effects of these mediators are comparable with those of angiotensin II are an interesting subject for further investigation.
